OrbusNeich Medical Group Holdings Limited

DB:Q8T Stock Report

Market Cap: €417.6m

OrbusNeich Medical Group Holdings Valuation

Is Q8T undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of Q8T when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Q8T (€0.51) is trading below our estimate of fair value (€2.3)

Significantly Below Fair Value: Q8T is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for Q8T?

Key metric: As Q8T is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for Q8T. This is calculated by dividing Q8T's market cap by their current earnings.
What is Q8T's PE Ratio?
PE Ratio11.2x
EarningsUS$38.72m
Market CapUS$434.91m

Price to Earnings Ratio vs Peers

How does Q8T's PE Ratio compare to its peers?

The above table shows the PE ratio for Q8T vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.7x
PHH2 Paul Hartmann
12.5xn/a€760.1m
SBS Stratec
32.1x25.4%€321.5m
DRW3 Drägerwerk KGaA
7.2x2.0%€796.1m
EUZ Eckert & Ziegler
23.2x5.9%€831.3m
Q8T OrbusNeich Medical Group Holdings
11.2x-3.1%€3.4b

Price-To-Earnings vs Peers: Q8T is good value based on its Price-To-Earnings Ratio (11.2x) compared to the peer average (18.7x).

Price to Earnings Ratio vs Industry

How does Q8T's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Q8T 11.2xIndustry Avg. 28.2xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: Q8T is good value based on its Price-To-Earnings Ratio (11.2x) compared to the European Medical Equipment industry average (28.2x).

Price to Earnings Ratio vs Fair Ratio

What is Q8T's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Q8T PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.2x
Fair PE Ratio31x

Price-To-Earnings vs Fair Ratio: Q8T is good value based on its Price-To-Earnings Ratio (11.2x) compared to the estimated Fair Price-To-Earnings Ratio (31x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst Q8T forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.51
€0.63
+25.2%
10.6%€0.71€0.55n/a3
Nov ’25€0.36
€0.63
+76.6%
10.6%€0.71€0.55n/a3
Oct ’25€0.39
€0.63
+63.8%
10.6%€0.71€0.55n/a3
Sep ’25€0.32
€0.63
+95.9%
10.6%€0.71€0.55n/a3
Aug ’25€0.32
€0.82
+155.2%
12.7%€0.93€0.68n/a3
Jul ’25€0.41
€0.81
+98.9%
12.7%€0.93€0.68n/a3
Jun ’25€0.53
€0.82
+53.9%
13.0%€0.94€0.68n/a3
May ’25€0.43
€0.82
+90.6%
13.0%€0.94€0.68n/a3
Apr ’25€0.34
€0.82
+138.6%
13.0%€0.94€0.68n/a3
Mar ’25€0.51
€1.00
+98.2%
10.2%€1.12€0.87n/a3
Feb ’25€0.59
€1.09
+85.1%
6.5%€1.17€1.00n/a3
Jan ’25€0.76
€1.16
+53.6%
1.0%€1.17€1.15n/a2
Dec ’24€0.68
€1.16
+71.8%
1.0%€1.17€1.15n/a2
Nov ’24€0.98
€1.16
+17.8%
1.0%€1.17€1.15€0.362
Oct ’24€0.97
€1.16
+19.0%
1.0%€1.17€1.15€0.392
Sep ’24€1.01
€1.16
+14.8%
1.0%€1.17€1.15€0.322
Aug ’24€1.02
€1.20
+18.0%
9.2%€1.31€1.09€0.322

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.18

7D

-2.7%

1Y

6.1%

Shandong Weigao Group Medical Polymer

HK$20.7b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.54

7D

-1.8%

1Y

-37.1%

LNA Santé

€242.3m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.8%

1Y

15.7%